Government of Belarus   Report issue

Government Phase 1 Phase 2 Phase 3
Founded: Minsk Belarus (1994)

Organization Overview

First Clinical Trial
2011
NCT02497443
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Director, the Institute of Biophysics and Cell Engineering of NAS of Belarus | Head of the Lab of Institute of Biophysics and Cell Engineering of NAS | Institute for biophysics and cellular engineering NAS of Belarus | Ministry of Health, Belarus | Ministry of Public Health, Republic of Belarus | National Anti Doping Laboratory, Belarus | State Institution of Nizhny Novgorod region Regional Center for Prevention and Control of AIDS and other infectious diseases | State Institution "Republican Scientific and Practical Center" Cardiology, Belarus | State Institution Republican Scientific and Practical Centre for Traumatology and Orthopedics of the Ministry of Health of the Republic of Belarus

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 3)

Breast Neoplasms (Phase 2)

Cardiovascular Diseases (Phase 2)

Coinfection (Phase 3)

Epilepsy (Phase 2)

Extensively Drug-Resistant Tuberculosis (Phase 3)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

HIV Infections (Phase 3)

Immunologic Deficiency Syndromes (Phase 3)

Lung Diseases, Interstitial (Phase 2)

Pneumonia (Phase 2)

Pneumonia, Viral (Phase 2)

Thrombosis (Phase 3)

Tuberculosis (Phase 3)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Venous Thrombosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 14